Suppr超能文献

遗传性和非典型性溶血性尿毒症综合征的预后:法国全国性系列研究比较儿童与成人患者

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

机构信息

Service d'Immunologie Biologique, Hôpital Europeén Georges Pompidou, 20-40 rue Leblanc, Paris cedex 15, France.

出版信息

Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62. doi: 10.2215/CJN.04760512. Epub 2013 Jan 10.

Abstract

BACKGROUND AND OBJECTIVES

Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease that was first recognized in children but also affects adults. This study assessed the disease presentation and outcome in a nationwide cohort of patients with aHUS according to the age at onset and the underlying complement abnormalities.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 214 patients with aHUS were enrolled between 2000 and 2008 and screened for mutations in the six susceptibility factors for aHUS and for anti-factor H antibodies.

RESULTS

Onset of aHUS occurred as frequently during adulthood (58.4%) as during childhood (41.6%). The percentages of patients who developed the disease were 23%, 40%, 70%, and 98% by age 2, 18, 40, and 60 years, respectively. Mortality was higher in children than in adults (6.7% versus 0.8% at 1 year) (P=0.02), but progression to ESRD after the first aHUS episode was more frequent in adults (46% versus 16%; P<0.001). Sixty-one percent of patients had mutations in their complement genes. The renal outcome was not significantly different in adults regardless of genetic background. Only membrane cofactor protein (MCP) and undetermined aHUS were less severe in children than adults. The frequency of relapse after 1 year was 92% in children with MCP-associated HUS and approximately 30% in all other subgroups.

CONCLUSION

Mortality rate was higher in children than adults with aHUS, but renal prognosis was worse in adults than children. In children, the prognosis strongly depends on the genetic background.

摘要

背景和目的

非典型溶血尿毒综合征(aHUS)是一种罕见的补体介导的肾脏疾病,最初在儿童中发现,但也影响成年人。本研究根据发病年龄和潜在补体异常,评估了全国范围内 aHUS 患者的疾病表现和结局。

设计、地点、参与者和测量:2000 年至 2008 年间共纳入 214 例 aHUS 患者,筛查其 6 种易感性因素和抗因子 H 抗体的突变。

结果

aHUS 的发病年龄在成年期(58.4%)和儿童期(41.6%)同样常见。到 2、18、40 和 60 岁时,分别有 23%、40%、70%和 98%的患者发病。儿童的死亡率高于成年人(1 年时为 6.7%比 0.8%;P=0.02),但成年人首次发生 aHUS 后进展为终末期肾病的比例更高(46%比 16%;P<0.001)。61%的患者存在补体基因的突变。成人无论遗传背景如何,肾脏结局均无显著差异。仅膜辅因子蛋白(MCP)和未明原因的 aHUS 在儿童中比成人轻。儿童 MCP 相关 HUS 患者在 1 年后的复发率为 92%,而其他所有亚组的复发率约为 30%。

结论

儿童 aHUS 的死亡率高于成年人,但成人的肾脏预后较儿童差。在儿童中,预后强烈取决于遗传背景。

相似文献

1
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.
Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62. doi: 10.2215/CJN.04760512. Epub 2013 Jan 10.
2
Atypical hemolytic uremic syndrome.
Orphanet J Rare Dis. 2011 Sep 8;6:60. doi: 10.1186/1750-1172-6-60.
3
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
Clin J Am Soc Nephrol. 2010 Oct;5(10):1844-59. doi: 10.2215/CJN.02210310. Epub 2010 Jul 1.
4
[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
Rev Med Interne. 2011 Apr;32(4):232-40. doi: 10.1016/j.revmed.2009.09.039. Epub 2011 Mar 3.
5
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.
J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884. Epub 2013 Feb 21.
6
Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
Kidney Int. 2019 Jun;95(6):1443-1452. doi: 10.1016/j.kint.2019.01.023. Epub 2019 Mar 15.
7
Complement Gene Variants and Shiga Toxin-Producing -Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):364-377. doi: 10.2215/CJN.05830518. Epub 2019 Jan 23.
9
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
J Am Soc Nephrol. 2007 Aug;18(8):2392-400. doi: 10.1681/ASN.2006080811. Epub 2007 Jun 28.
10
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
J Am Soc Nephrol. 2006 Jul;17(7):2017-25. doi: 10.1681/ASN.2005101051. Epub 2006 Jun 8.

引用本文的文献

3
Characterizing the association between complement-mediated TMA and cognitive dysfunction using MRI and neurocognitive assessment.
Blood Vessel Thromb Hemost. 2024 Jun 24;1(3):100016. doi: 10.1016/j.bvth.2024.100016. eCollection 2024 Sep.
4
Demographics and baseline disease characteristics of UK patients within the global aHUS registry.
BMC Nephrol. 2025 Aug 5;26(1):434. doi: 10.1186/s12882-025-04321-x.
5
Influenza A H1N1 Triggering Complement-Mediated Hemolytic Uremic Syndrome.
J Med Cases. 2025 Jul 19;16(7):254-258. doi: 10.14740/jmc5129. eCollection 2025 Jul.
6
Neurological Manifestations of Hemolytic Uremic Syndrome: A Comprehensive Review.
Brain Sci. 2025 Jul 4;15(7):717. doi: 10.3390/brainsci15070717.
7
It's Friday, 3 p.m., and the phone rings ... a practical approach to common nephrology consultations-Part 1.
Clin Kidney J. 2025 Feb 12;18(4):sfaf043. doi: 10.1093/ckj/sfaf043. eCollection 2025 Apr.
8
Complement System Inhibitors in Nephrology: An Update-Narrative Review.
Int J Mol Sci. 2025 Jun 19;26(12):5902. doi: 10.3390/ijms26125902.
9
Atypical Hemolytic Uremic Syndrome/Complement-Mediated Thrombotic Microangiopathy Triggered by SARS-CoV-2 Infection: A Case Report.
Case Rep Nephrol Dial. 2025 Apr 28;15(1):119-124. doi: 10.1159/000545798. eCollection 2025 Jan-Dec.

本文引用的文献

1
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2.
2
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.
Am J Transplant. 2012 Dec;12(12):3337-54. doi: 10.1111/j.1600-6143.2012.04252.x. Epub 2012 Sep 7.
3
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
Blood. 2012 May 3;119(18):4182-91. doi: 10.1182/blood-2011-10-383281. Epub 2012 Jan 13.
4
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.
Mol Immunol. 2012 Jan;49(4):640-8. doi: 10.1016/j.molimm.2011.11.003. Epub 2011 Dec 5.
5
Age-related penetrance of hereditary atypical hemolytic uremic syndrome.
Ann Hum Genet. 2011 Nov;75(6):639-47. doi: 10.1111/j.1469-1809.2011.00671.x. Epub 2011 Sep 12.
6
Alternative complement pathway assessment in patients with atypical HUS.
J Immunol Methods. 2011 Feb 28;365(1-2):8-26. doi: 10.1016/j.jim.2010.12.020. Epub 2011 Jan 6.
7
Targeting complement C5 in atypical hemolytic uremic syndrome.
J Am Soc Nephrol. 2011 Jan;22(1):7-9. doi: 10.1681/ASN.2010111145. Epub 2010 Dec 2.
8
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.
J Am Soc Nephrol. 2010 Dec;21(12):2180-7. doi: 10.1681/ASN.2010030315. Epub 2010 Nov 4.
9
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
Clin J Am Soc Nephrol. 2010 Oct;5(10):1844-59. doi: 10.2215/CJN.02210310. Epub 2010 Jul 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验